Cited 47 times in
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2022-12-22T01:28:45Z | - |
dc.date.available | 2022-12-22T01:28:45Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191236 | - |
dc.description.abstract | Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for EGFR-mutant non-small-cell lung cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Acrylamides / adverse effects | - |
dc.subject.MESH | Acrylamides / therapeutic use | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aniline Compounds / adverse effects | - |
dc.subject.MESH | Aniline Compounds / therapeutic use | - |
dc.subject.MESH | Antibodies, Bispecific / adverse effects | - |
dc.subject.MESH | Antibodies, Bispecific / therapeutic use | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / adverse effects | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / pathology | - |
dc.subject.MESH | ErbB Receptors / antagonists & inhibitors | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms / drug therapy* | - |
dc.subject.MESH | Lung Neoplasms / genetics | - |
dc.subject.MESH | Lung Neoplasms / pathology | - |
dc.subject.MESH | Morpholines / adverse effects | - |
dc.subject.MESH | Morpholines / therapeutic use | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Protein Kinase Inhibitors / adverse effects | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use* | - |
dc.subject.MESH | Pyrazoles / adverse effects | - |
dc.subject.MESH | Pyrazoles / therapeutic use | - |
dc.subject.MESH | Pyrimidines / adverse effects | - |
dc.subject.MESH | Pyrimidines / therapeutic use | - |
dc.subject.MESH | Research Design | - |
dc.subject.MESH | Young Adult | - |
dc.title | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Enriqueta Felip | - |
dc.contributor.googleauthor | Hidetoshi Hayashi | - |
dc.contributor.googleauthor | Michael Thomas | - |
dc.contributor.googleauthor | Shun Lu | - |
dc.contributor.googleauthor | Benjamin Besse | - |
dc.contributor.googleauthor | Tao Sun | - |
dc.contributor.googleauthor | Melissa Martinez | - |
dc.contributor.googleauthor | Seema N Sethi | - |
dc.contributor.googleauthor | S Martin Shreeve | - |
dc.contributor.googleauthor | Alexander I Spira | - |
dc.identifier.doi | 10.2217/fon-2021-0923 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J00914 | - |
dc.identifier.eissn | 1744-8301 | - |
dc.identifier.pmid | 34911336 | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/fon-2021-0923?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed | - |
dc.subject.keyword | EGFR mutations | - |
dc.subject.keyword | amivantamab | - |
dc.subject.keyword | lazertinib | - |
dc.subject.keyword | non-small-cell lung cancer | - |
dc.subject.keyword | tyrosine kinase inhibitors | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 18 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 639 | - |
dc.citation.endPage | 647 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, Vol.18(6) : 639-647, 2022-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.